We are live on ! Find out more
ANAB icon

AnaptysBio

113 hedge funds and large institutions have $675M invested in AnaptysBio in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 36 increasing their positions, 36 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more call options, than puts

Call options by funds: $1.47M | Put options by funds: $1.34M

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 36

5% less funds holding

Funds holding: 119 → 113 (-6)

6.8% less ownership

Funds ownership: 115.97% → 109.17% (-6.8%)

30% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 20

50% less capital inflows, than outflows

Capital inflows: $49.9M | Capital outflows: $100M

Holders
113
Holders Change
-6
Holders Change %
-5.04%
% of All Funds
1.8%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
36
Reduced
36
Closed
20
Calls
$1.47​M
Puts
$1.34​M
Net Calls
+$135​K
Net Calls Change
+$64​K

ANAB Hedge Fund Activity: Q1 2023 in Review

113 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q1 2023, worth a combined $675M — down 34% from $1.02B a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ANAB and 14 opened new positions — a net loss of 6 holders — while 36 trimmed existing stakes and 36 added.

The largest buyer was Great Point Partners, adding an estimated $19.2M. The largest seller was Federated Hermes, cutting an estimated $25.1M.

  • 113 institutional investors held AnaptysBio (ANAB) as of Q1 2023, down from 119 in Q4 2022.
  • Funds reported $675M of AnaptysBio stock for Q1 2023, down 34% quarter-over-quarter.
  • 14 funds opened new AnaptysBio positions in Q1 2023 and 20 closed out, a net change of -6 holders.
  • The largest AnaptysBio buyer in Q1 2023 was Great Point Partners, an estimated $19.2M added.
  • The largest AnaptysBio seller in Q1 2023 was Federated Hermes, an estimated $25.1M sold.

Based on aggregated 13F filings for Q1 2023.